Discounted Cash Flow
Ginkgo Bioworks Holdings, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $54.2m | $-119.9m | $-66.9m | -221.2% | $-0.10 |
| 2020 | $76.7m (41.5%) | $-126.7m (-5.7%) | $-193.7m (-189.5%) | -165.3% (25.3%) | $-0.10 (4.7%) |
| 2021 | $313.8m (309.4%) | $-1.8b (-1349.3%) | $-310.3m (-60.3%) | -585.2% (-254.0%) | $-1.35 (-1258.7%) |
| 2022 | $477.7m (52.2%) | $-2.1b (-14.7%) | $-304.5m (1.9%) | -440.9% (24.7%) | $-1.25 (7.1%) |
| 2023 | $251.5m (-47.4%) | $-892.9m (57.6%) | $-336.3m (-10.5%) | -355.1% (19.5%) | $-0.46 (63.4%) |
| 2024 | $227.0m (-9.7%) | $-547.0m (38.7%) | $-382.1m (-13.6%) | -240.9% (32.1%) | $-10.54 (-2195.6%) |
| 2025 | $170.2m (-25.1%) | $-312.8m (42.8%) | $-178.7m (53.2%) | -183.8% (23.7%) | $-5.64 (46.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.